A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease)

Recently, it has been recognized that elevated resting heart rate (HR) is an independent risk factor for all-cause and cardiovascular mortality, not only in the general population, but also in patients with cardiovascular disease. Ivabradine is a specific inhibitor of the I-f current in the sinoatrial node providing a pure HR reduction without modification of other cardiovascular parameters. Treatment with ivabradine therefore provides an opportunity to assess the effects of lowering HR without directly altering other aspects of cardiac function. Ivabradine has been proven to effectively prevent myocardial ischaemia and treat symptoms in patients with chronic stable angina pectoris. The BEAUTI(f)UL trial sheds new light on the role of HR control in cardiovascular disease and shows that ivabradine in patients with HR above 70 b.p.m. prevents coronary outcomes. These are particularly important data because they have been obtained on top of the best possible preventive therapy, including beta-blockers. BEAUTI(f)UL has also led to a series of stimulating hypotheses that constitute the rationale for another trial called SIGNI(f)Y, which will enrol patients with coronary artery disease (CAD) and normal left ventricular function with a resting HR of >= 70 b.p.m. The primary endpoint will take into consideration only CAD outcomes, i.e. CV mortality and hospitalization for myocardial infarction. So SIGNI(f)Y will be a logical extension of BEAUTI(f)UL.